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ABSTRACT
Background Raising awareness of possible cancer symptoms is important for timely help-seeking; recent campaigns have focused on symptom
groups (such as abdominal symptoms) rather than individual alarm symptoms associated with particular cancer sites. The evidence base
supporting such initiatives is still emerging however; understanding the frequency and nature of presenting abdominal symptoms among cancer
patients could inform the design and evaluation of public health awareness campaigns.
Methods We examined eight presenting abdominal symptoms (abdominal pain, change in bowel habit, bloating/distension, dyspepsia, rectal
bleeding, dysphagia, reflux and nausea/vomiting) among 15 956 patients subsequently diagnosed with cancer in England. We investigated the
cancer site case-mix and variation in the patient interval (symptom-onset-to-presentation) by abdominal symptom.
Results Almost a quarter (23%) of cancer patients presented with abdominal symptoms before being diagnosed with one of 27 common and
rarer cancers. The patient interval varied substantially by abdominal symptom: median (IQR) intervals ranged from 7 (0–28) days for abdominal
pain to 30 (4–73) days for dysphagia. This variation persisted after adjusting for age, sex and ethnicity (P < 0.001).
Conclusions Abdominal symptoms are common at presentation among cancer patients, while time to presentation varies by symptom. The
need for awareness campaigns may be greater for symptoms associated with longer intervals to help-seeking.
Keywords cancer, health promotion, public health
Introduction
Diagnosing cancer early in symptomatic patients is a
prominent feature of contemporary cancer control strat-
egies.1,2 A range of pioneering studies during the last
decade have established associations between the knowl-
edge (‘awareness’) of likely symptoms of cancer among
the general public and timely presentation, diagnosis,
and outcomes.3–6 Public health agencies have conse-
quently implemented educational interventions aimed at
raising awareness of cancer symptoms in order to pro-
mote timely presentation.7–9 However, the evidence base
supporting the design of such interventions is still
emerging.
Previous symptom awareness campaigns have tended to
take a cancer-based approach, by targeting ‘red-flag’ or
‘alarm’ symptoms explicitly associated with specific cancers,
such as ‘blood in poo’ and colorectal cancer.10–12 There is
however growing interest in targeting symptoms relating to a
body area or system, partly as this provides an opportunity
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to promote the earlier presentation of rarer and less com-
mon cancers. In England, an abdominal symptoms cam-
paign was recently piloted at regional level, focusing on a
range of symptoms (diarrhoea, bloating, abdominal discom-
fort, constipation, nausea, and blood in poo).13
Examining the length of the patient interval (time from
symptom onset to presentation) associated with different
abdominal symptoms can contribute to the design of future
campaigns. Awareness campaigns about possible cancer symp-
toms aim to shorten the patient interval by encouraging timely
symptom appraisal and help-seeking.14 Therefore, symptom-
specific patient intervals may be interpreted as measures of
relative need for such interventions.15 Alongside considerations
of other important factors such as the predictive value of a
symptom for cancer, and the prevalence of different symptoms
in the general population, such evidence can support how the
content of awareness campaigns could prioritize certain symp-
toms over others.
Further, estimating the impact of a symptom awareness
campaign has been shown to be challenging due to the diffuse
and broad-reaching nature of campaigns; such difficulties are
likely to be exacerbated by symptom-based approaches that
target more than one cancer site.7,16 Evidence regarding the
anticipated cancer site case-mix of a particular symptom could
help guide the direction of evaluation strategies, though such
evidence is generally lacking.17
We therefore examined the frequency of abdominal symp-
toms at presentation in a representative population of inci-
dent cancer patients; described the range of cancers
associated with abdominal symptoms in an incident cohort;
and examined variation in the length of the patient interval
by presenting abdominal symptom.
Methods
Data source
We used data from the first English cancer audit (National
Audit of Cancer Diagnosis in Primary Care) 2009–10, details
of which have been described previously.18 Briefly, partici-
pating clinicians collected information on the diagnostic pro-
cess for incident cancer patients in ~14% of all general
practices in England, excluding screen-detected cases. The
audited cancer patient population was representative of inci-
dent cancer patients in England during the same period,
while the characteristics of participating practices were found
to be comparable to non-participating practices.18,19
Patient population
We analysed data from cancer patients with complete and
valid information on age group (among patients aged 15
years or older), sex, presenting symptoms and cancer site
(see Supplementary Fig. S1 for flow chart of sample deriv-
ation). Individuals diagnosed incidentally and those with can-
cer sites categorized as ‘No information’ and ‘Unknown
Primary’ were excluded from the analysis. Among the 3661
cancer patients with one or more abdominal symptoms,
2936 (80%) had complete information on the patient inter-
val (see Supplementary Table S2 for the proportion of miss-
ing values by individual symptom). Overall, the strongest
predictor of missing interval or pre-referral consultation data
was first presentation to a healthcare facility other than the
patient’s own general practice, without evidence for substan-
tive differences by socio-demographic characteristic (data
not shown).
Variables of interest
General practitioners participating in the audit provided free
text answers to the question ‘what was the main presenting
symptom?’ for each patient, based on information in their pri-
mary care records. As described previously,20 we coded symp-
tom constructs following principles of natural language
processing (NLP), without prior definitions or restrictions
regarding cancer-symptom associations.21 If multiple symp-
toms were mentioned, they were assumed to be synchronous.
Symptoms were initially assigned by MMK, and cross-validated
by GL and GPR, an approach also used previously.20 Based on
the abdominal symptoms described by the 2015 National
Institute for Health and Care Excellence (NICE) guidelines for
suspected cancer, we selected a total of 18 symptom constructs
(see Supplementary Table S2) which were further aggregated
into eight abdominal symptom groups: (non-acute) abdominal
pain, bloating or distension, change in bowel habit, dysphagia,
dyspepsia, nausea or vomiting, rectal bleeding and reflux.22
The patient interval was defined as the number of days
between symptom onset and the first presentation to pri-
mary care, in line with the Aarhus Statement.23
Statistical analysis
The frequency (and associated exact confidence intervals) of
abdominal symptoms in the studied population of cancer
patients were estimated. We then described the cancer site
case-mix of abdominal symptoms, namely the range and
relative frequencies (proportions) of different cancer sites
subsequently diagnosed among cancer patients presenting
with abdominal symptoms.
Subsequently, we examined variation in the patient interval
by abdominal symptom. As public awareness campaigns target
individual symptoms rather than symptom combinations,
these analyses were restricted to the majority of cancer patients
THE NATURE AND FREQUENCY OF ABDOMINAL SYMPTOMS IN CANCER PATIENTS e389
D
ow
nloaded from
 https://academ
ic.oup.com
/jpubhealth/article-abstract/40/3/e388/4827055 by guest on 15 O
ctober 2018
with a single recorded presenting abdominal symptom (n =
2253, 62% of all patients reporting an abdominal symptom)—
though we examined common abdominal symptom combina-
tions in supplementary analyses. Firstly, the mean, median,
interquartile range and 90th centiles of the patient interval
were estimated for each abdominal symptom along with 95%
confidence intervals using a bootstrap approach with 1000
replications. Kruskal–Wallis tests were used to test variation in
median interval length by abdominal symptom. The propor-
tion of patients with each symptom that experienced a patient
interval of 60 days or longer was also calculated to help to fur-
ther contextualize the findings.
We then used generalized linear models (GLM) to examine
the association between abdominal symptoms and the patient
interval adjusted for age group (parameterized as <50 years,
50–69 years, 70+ years), ethnicity (white, non-white) and sex
(men, women) given prior evidence supporting their associa-
tions with diagnostic timeliness.24 To account for skewed out-
come data, a log link function was used (which allows the
covariates to be modelled on a linear additive scale, aiding
interpretation), and significance testing was based on boot-
strapping (1000 replications). Variation in interval length was
examined using joint Wald tests, with statistical significance at
the 5% level. All analyses were conducted using STATA SE v
13.1 (StataCorp, College Station, TX, USA).
Supplementary analyses
We conducted supplementary analyses examining the fre-
quency of 12 most common abdominal symptom combina-
tions, and their associated distributions of the observed
patient interval in the same way as described above.
Results
Frequency of presenting abdominal symptoms in
cancer patients
Of a total of 15 956 patients with cancer, 3661 (23%) pre-
sented with one or more abdominal symptoms. Abdominal
pain was the most common abdominal symptom across the
entire cohort of cancer patients (8%), followed by change in
bowel habit (6%), and rectal bleeding (5%) (Table 1).
Cancer site case-mix of abdominal symptoms in
cancer patients
Among the 3661 cancer patients who presented with
abdominal symptoms, the majority (89%, 3244/3661) were
diagnosed with solid cancers of abdominal or adjacent
organs (Fig. 1). The most commonly diagnosed cancer site
was colorectal cancer (47%), followed by oesophageal
(13%), ovarian (7%) and pancreatic (6%) cancers (Table 2
and Fig. 1). A further 14 cancer sites were represented
among the remainder of patients, including solid tumours of
non-abdominal (and non-adjacent) organs (8%) and haem-
atological cancers (4%).
We also considered the relative importance of abdominal
symptoms for each cancer site by calculating the proportion
of patients with a given cancer who had presented with one
or more abdominal symptoms. Unsurprisingly, over two-
fifths (41%) of cancer patients diagnosed with an abdominal
cancer had presented with abdominal symptoms, although
this ranged from 84% of patients later diagnosed with
oesophageal cancer to 5% of patients later diagnosed with
prostate cancer (see Table 2 for full breakdown). Patients
with cancers arising outside the abdominal region were
much less likely to report abdominal symptoms (4%, n =
279). In contrast, patients diagnosed with haematological
cancers were relatively more likely to report abdominal
symptoms at presentation (11%, n = 138), almost two-thirds
of those being patients with lymphoma (Table 2).
Patient interval by presenting abdominal symptom
Among cancer patients with a single presenting abdominal
symptom (n = 2253), there was strong evidence for variation
in the patient interval (symptom-onset-to-presentation) by
symptom (P < 0.001, Fig. 2 and Supplementary Table S3).
Patients presenting with change in bowel habit or dysphagia
had the longest patient intervals: one in two patients with
either of these symptoms waited at least a month before
presentation, while a quarter waited 2 months or longer
(median (IQR) patient interval: 30(4–73) days for change in
Table 1 Frequency of abdominal symptoms among symptomatic cancer
patients (n = 15 956)
Symptom No. of patients Percentage of symptomatic
cancer patients (95% CI)
Abdominal pain 1268 7.9 (7.5–8.4)
Change in bowel habit 1010 6.3 (6.0–6.7)
Rectal bleeding 768 4.8 (4.5–5.2)
Dysphagia 418 2.6 (2.4–2.9)
Nausea or vomiting 261 1.6 (1.5–1.8)
Dyspepsia 256 1.6 (1.4–1.8)
Bloating or distension 250 1.6 (1.4–1.8)
Reflux 71 0.4 (0.4–0.6)
Any abdominal symptom 3661 22.9 (22.3–23.6)
NB the number of patients (percentages) sum to more than 3661 (23%)
as patients could have more than one abdominal symptom.
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bowel habit; and 30(10–61) days for dysphagia). A consider-
able proportion (25–30%) of patients with bloating or dis-
tension, reflux and rectal bleeding also waited for two
months or longer before presentation. In contrast, cancer
patients presenting with abdominal pain or nausea/vomiting
went to the doctor sooner on average (7(0–28) days and 7-
(0–23) days, respectively). The variation in interval length by
abdominal symptom persisted after adjusting for age group,
sex and ethnicity (Supplementary Table S4).
In supplementary analyses, we considered the 12 most
common categories of single or combinations of presenting
symptoms, including 3438 patients (94% of patients report-
ing one or more abdominal symptom). Results were largely
comparable to the main analyses finding in respect of asso-
ciations with the patient interval (see Supplementary Tables
S5 and S6).
Discussion
Main findings of this study
Almost one in four cancer patients presented with abdominal
symptoms before diagnosis. The majority of cancer patients
who presented with abdominal symptoms were subsequently
diagnosed with a range of common and rarer cancers of
abdominal or adjacent organs, but a proportion of patients
had tumours of other solid organ tumours, or haematological
malignancies. The median patient interval ranged from 7 days
for abdominal pain to 30 days for dysphagia. The observed
differences in interval length by abdominal symptom remained
when adjusted for age, sex and ethnicity.
What is already known on this topic
In our study, colorectal, oesophageal, ovarian and pancreatic
cancers accounted for the majority of cancer patients that pre-
sented with one or more abdominal symptoms, consistent
with previous evidence.25,26 However, we also found large
proportions of patients diagnosed with rarer cancers such as
stomach (65%), small intestinal (69%) and gallbladder cancers
(51%) presenting with abdominal symptoms.
Comparable evidence on the association between the
patient interval and abdominal symptoms is limited to two
English studies on colorectal and pancreatic cancers, respect-
ively.26,27 Rectal bleeding and dyspepsia-like symptoms were
associated with shorter time to presentation compared with
other studied symptoms, in line with our findings regarding
these symptoms.26
What this study adds
In order to improve the timeliness of diagnosis among can-
cer patients who present with symptoms, we need a better
appreciation of the nature and frequency of presenting
symptoms among these patients; currently, related epidemio-
logical evidence is limited in quantity and breadth17.
Consequently, our study adds substantially to the present
evidence base, both regarding the burden of abdominal
symptoms in incident cancer patients, and their associations
with time to help-seeking. Abdominal symptoms appear to
be common among incident cases of cancer, suggesting that
symptom awareness campaigns focusing on abdominal
symptoms could potentially expedite the diagnosis of a large
range of both common and rarer cancers.
Previous analyses have shown large variation in the
patient interval by cancer site.28,29 Our findings suggest that
this chiefly reflects variation in interval length of the most
frequent symptoms of the different cancers. After consider-
ing symptom prevalence and predictive values of each symp-
tom, variation in the length of the patient interval associated
with different symptoms could help to identify particular
symptoms for prioritization in campaigns. For example, we
found that one in two cancer patients with dysphagia waited
almost a month before presenting. As dysphagia is also an
established ‘alarm’ symptom for cancer, this finding argues
for its further targeting by future campaigns.30 In contrast,
cancer patients with abdominal pain presented after a
median interval of 7 days, and given its high prevalence and
Fig. 1 Cancer site case-mix of patients who presented with one or more abdominal symptom (n = 3661). NB Proportions of the nine most frequent cancers
across all abdominal symptoms shown only; other cancer diagnoses are represented as ‘Any other cancer site’ category. See Table 2 for exact proportions.
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low predictive value, there may be little to be gained by rais-
ing its awareness amongst the general population.31,32
Previous evaluations have examined the increase in num-
ber of ‘2-week wait’ referrals, the corresponding conversion
rates to cancer cases, and diagnostic activity.33 For cam-
paigns targeting groups of symptoms, understanding the
anticipated range of affected cancer sites will be crucial for
accurate assessment of the campaign’s impact.
Limitations of this study
The study design enabled analysis of data on both the pre-
senting symptoms and associated patient intervals among a
Table 2 Cancer site case-mix of patients with one or more abdominal symptoms (n=3661) and proportion of patients with a given cancer that had
abdominal symptoms
Cancer Number of patients Percentage of patients with one or more
abdominal symptoms subsequently
diagnosed with a given cancer (95% CI)
Percentage of patients with a given
cancer who had one or more abdominal
symptoms
Abdominal cancersa
Colorectal 1737 47.4 (45.8–49.1) 75 (73–77)
Oesophageal 468 12.8 (11.7–13.9) 84 (80–87)
Ovarian 267 7.3 (6.5–8.2) 70 (65–74)
Pancreatic 214 5.8 (5.1–6.7) 59 (54–64)
Stomach 189 5.2 (4.5–5.9) 65 (60–71)
Prostate 110 3.0 (2.5–3.6) 5 (4–6)
Renal 89 2.4 (2.0–3.0) 29 (24–34
Bladder 40 1.1 (0.8–1.5) 5 (4–7)
Liver 38 1.0 (0.8–1.4) 44 (34–54)
Small intestine 36 1.0 (0.7–1.4) 69 (56–80)
Gallbladder 32 0.9 (0.6–1.2) 51 (39–63)
Endometrial 24 0.7 (0.4–1.0) 6 (4–9)
Sub-total 3244 88.6 (87.5–89.6) 41.0 (39.9–42.1)
Other cancers
Lung 91 2.5 (2.0–3.0) 5 (4–6)
Oropharyngeal 20 0.5 (0.4–0.8) 10 (6–14)
Breast 14 0.4 (0.2–0.6) 0.5 (0.3–0.9)
Laryngeal 12 0.3 (0.2–0.6) 10 (6–17)
Brain 10 0.3 (0.1–0.5) 5 (3–8)
Cervical 10 0.3 (0.1–0.5) 8 (4–14)
Sarcomab 10 0.3 (0.1–0.5) 10 (5–17)
Testicular 5 0.1 (0.1–0.3) 3 (1–8)
Melanoma 4 0.1 (0.04–0.3) 0.5 (0.2–1.3)
Mesothelioma 4 0.1 (0.04–0.3) 6 (2–14)
Thyroid 4 0.1 (0.04–0.3) 4 (2–10)
Sub-total 279c 7.6 (6.8–8.5)c 4.1 (3.6–4.6)c
Haematological cancers
Lymphomab 97 2.6 (2.2–3.2) 15 (12–18)
Leukaemia 25 0.7 (0.5–1.0) 7 (5–11)
Myeloma 16 0.4 (0.3–0.7) 8 (5–13)
Sub-total 138 3.8 (3.2–4.4) 11.5 (9.8–13.4)
Total 3661c 100c 23c
aDefined as cancers arising in the intra-abdominal organs, together with oesophageal and prostate cancer NB ordered by frequency among patients with
abdominal symptoms.
bIt is likely that a proportion of sarcomas and lymphomas were intra-abdominal but information regarding their exact location was not available.
cIncludes 95 cases described as ‘Other’ cancers.
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large and representative cancer patient population in
England. Our findings of symptom prevalence across a rep-
resentative cohort of patients diagnosed with 1 of 28 cancer
sites substantially augment previous evidence dominated by
cancer site-specific symptom studies.25–27,30,34
There are several limitations. Firstly, data on symptoms and
the patient interval used in our study is reliant on the infor-
mation on presenting symptoms and their duration being
accurately and completely declared or elicited during consult-
ation, and recorded in the patient’s record. Nonetheless such
approaches enable the profiling of large patient groups with-
out potential concern about recall or survivorship bias.29,35 A
minority of patients with abdominal symptoms had missing
outcome data regarding the patient interval, as noted in simi-
lar studies in this field.26,27,36,37
We restricted our analyses to eight abdominal symptoms
based on those recommended for urgent referral in national
clinical guidelines.22 This was a pragmatic decision that has
face validity as symptom awareness campaigns are unlikely
to include symptoms with a very low predictive value. We
examined the patient interval among patients with a single
abdominal symptom for ease of interpretation, again
because campaign messages have thus far focused on single
symptoms as opposed to synchronous symptom combina-
tions. Further, in sensitivity analyses considering the most
frequent symptom combination groups among nearly all
cancer patients who presented with one or more abdominal
symptom, we found concordant findings (see Supplementary
Table S5 and S6).
Our analysis focuses on the significance of abdominal
symptoms among patients subsequently diagnosed with can-
cer, and provides insight into how awareness campaigns may
be evaluated. Nevertheless, it is clear that abdominal symp-
toms in primary care may represent other important dis-
eases, such as inflammatory bowel disease.26,38 Coordinating
our findings with evidence regarding the prevalence of
abdominal symptoms among the general population, and the
potential diagnostic experiences of patients that seek help
for such symptoms beyond the cancer context may bring
further insight.39,40 We were unable to examine variation in
patient interval by comorbidity status or deprivation: symp-
tom appraisal and therefore the length of the patient inter-
val, may be influenced by the presence of other conditions,
and lower socioeconomic groups tend to experience lowest
symptom knowledge and longer time to presentation.41–43
However, such associations, if present, are unlikely to sub-
stantially confound the observed variation by abdominal
symptom, which is the main focus of our study. Finally,
while our findings provide insight into the associations
between symptoms and timeliness of help-seeking before
major population level campaigns were launched (in 2011),
further examination of these associations between symptoms
and timeliness of help-seeking in more recent cohorts will
provide further insight.33
Conclusions
In conclusion, almost a quarter of all patients with cancer
initially present with an abdominal symptom, and their inter-
val to presentation varies substantially by (abdominal) symp-
tom type. The timeliness of presentation associated with
individual symptoms could inform the design of campaigns,
while the cancer site case-mix of a particular symptomatic
presentation could be used to inform evaluation.
Supplementary data
Supplementary data are available at the Journal of Public
Health online.
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